Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 11/20 | 0.62 |
| ▸ | PDE4A | P27815 | 9/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.62 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.62 |
| ▸ | PDE5A | O76074 | 3/20 | 0.55 |
| ▸ | PDE1A | P54750 | 1/20 | 0.55 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.55 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9944107 | 0.90 | PDE4A (0.54) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL1458268 | 0.85 | PDE4A (0.56) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL1458274 | 0.83 | PDE4A (0.55) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL1459185 | 0.82 | PDE4D (0.54) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL1457754 | 0.81 | PDE4A (0.52) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL9944086 | 0.81 | PDE4A (0.49) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL1458062 | 0.81 | PDE4A (0.51) | PDE4DPDE4APDE4BPDE4CMEN1 | |
| SCHEMBL9944142 | 0.81 | PDE4D (0.54) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL1458427 | 0.81 | PDE4A (0.60) | PDE4DPDE4APDE4BPDE4CPDE5A | |
| SCHEMBL1459181 | 0.81 | PDE4D (0.57) | PDE4DPDE4APDE4BPDE4CPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447028-B2 | Therapeutic aryl-amido-aryl compounds and their use | KING'S COLLEGE LONDON (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20160039747-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2016-02-11 | — | — | US | disclosed |
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | RARA, RARB, RARG | PDE4D 664/4885PDE4A 358/4885PDE4B 512/4885 |
| US-20160039747-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | RARA, RARB, RARG | PDE4D 664/4885PDE4A 358/4885PDE4B 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.